Heliyon (Jan 2024)
Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systems
- Denis Horgan,
- Marc Van den Bulcke,
- Umberto Malapelle,
- Giancarlo Troncone,
- Nicola Normanno,
- Ettore D. Capoluongo,
- Arsela Prelaj,
- Carmelo Rizzari,
- Dario Trapani,
- Jaya Singh,
- Marta Kozaric,
- John Longshore,
- Manuel Ottaviano,
- Stefania Boccia,
- Gabriella Pravettoni,
- Ivana Cattaneo,
- Núria Malats,
- Reinhard Buettner,
- Karim Lekadir,
- Francesco de Lorenzo,
- Paul Hofman,
- Ruggero De Maria
Affiliations
- Denis Horgan
- European Alliance for Personalised Medicine, Brussels, Belgium; Department of Molecular and Cellular Engineering, Jacob Institute of Biotechnology and Bioengineering, Faculty of Engineering and Technology, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj - 211007, Uttar Pradesh India; Corresponding author. European Alliance for Personalised Medicine, Brussels, Belgium.
- Marc Van den Bulcke
- Belgian Cancer Centre, Sciensano, Brussels, Belgium
- Umberto Malapelle
- Department of Public Health, University Federico II of Naples, 80131 Naples, Italy
- Giancarlo Troncone
- Department of Public Health, University Federico II of Naples, 80131 Naples, Italy
- Nicola Normanno
- Istituto Nazionale Tumori ''Fondazione G. Pascale'' - IRCCS, Naples, Italy
- Ettore D. Capoluongo
- Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Naples, Italy; Department of Clinical Pathology and Genomics, Azienda Ospedaliera Per L'Emergenza Cannizzaro, Catania, Italy
- Arsela Prelaj
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
- Carmelo Rizzari
- Unità di Ematologia Pediatrica, Fondazione MBBM, Università di Milano-Bicocca, Monza, Italy
- Dario Trapani
- European Institute of Oncology, IRCCS, 20141 Milan, Italy
- Jaya Singh
- European Alliance for Personalised Medicine, Brussels, Belgium
- Marta Kozaric
- European Alliance for Personalised Medicine, Brussels, Belgium
- John Longshore
- Astra Zeneca, 1800 Concord Pike, Wilmington, DE 19803, USA
- Manuel Ottaviano
- Departamento de Tecnología Fotónica y Bioingeniería, Universidad Politècnica de Madrid, 28040 Madrid, Spain
- Stefania Boccia
- Section of Hygiene, Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy; Departments of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- Gabriella Pravettoni
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Applied Research Division for Cognitive and Psychological Science, European Institute of Oncology (IEO) IRCCS, Milan, Italy
- Ivana Cattaneo
- Novartis Farma SpA, 21040 Origgio, Italy
- Núria Malats
- Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain
- Reinhard Buettner
- Lung Cancer Group Cologne, Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany
- Karim Lekadir
- Artificial Intelligence in Medicine Lab (BCN-AIM), Universitat de Barcelona, Barcelona, Spain
- Francesco de Lorenzo
- European Cancer Patient Coalition, Brussels, Belgium
- Paul Hofman
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Université Côte d'Azur, 06000 Nice, France
- Ruggero De Maria
- Institute of General Pathology, Catholic University of the Sacred Heart, Rome, Italy
- Journal volume & issue
-
Vol. 10,
no. 1
p. e23914
Abstract
Next-generation sequencing (NGS) and liquid biopsy (LB) showed positive results in the fight against different cancer types. This paper aims to assess the uptake of advanced molecular diagnostics/NGS for quick and efficient genetic profiles of tumour cells. For that purpose, the European Alliance for Personalised Medicine conducted a series of expert interviews to ascertain the current status across member states. One stakeholder meeting was additionally conducted to prioritize relevant factors by stakeholders. Seven common pillars were identified, and twenty-five measures were defined based on these pillars. Results showed that a multi-faceted approach is necessary for successful NGS implementation and that regional differences may be influenced by healthcare policies, resources, and infrastructure. It is important to consider different correlations when interpreting the results and to use them as a starting point for further discussion.
